Nuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual Meeting
Go back to Nuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual Meeting| Nuvel Holdings, Inc. (NASDAQ: NUVL) | Delayed: 123.42 -0.01 (0.01%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $123.43 | 52 Week High | $0.40 | |||
| Open | $123.50 | 52 Week Low | $0.14 | |||
| Day High | $123.56 | P/E | N/A | |||
| Day Low | $123.38 | EPS | $-0.56 | |||
| Volume | 2,094,308 | |||||
